Lexaria Bioscience Corp.
LEXX
$0.58
-$0.10-14.96%
NASDAQ
| 08/31/2025 | 05/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 0.00% | 0.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.00% | 0.00% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 0.00% | 0.00% | |||
| SG&A Expenses | -36.47% | -2.60% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -32.50% | 34.17% | |||
| Operating Income | 34.01% | -36.33% | |||
| Income Before Tax | 28.85% | -39.51% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 28.85% | -39.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -6.67% | -60.53% | |||
| Net Income | 28.85% | -39.65% | |||
| EBIT | 34.01% | -36.33% | |||
| EBITDA | 34.04% | -35.32% | |||
| EPS Basic | 33.51% | -33.70% | |||
| Normalized Basic EPS | 38.44% | -30.61% | |||
| EPS Diluted | 33.51% | -33.70% | |||
| Normalized Diluted EPS | 38.44% | -30.61% | |||
| Average Basic Shares Outstanding | 6.98% | 4.49% | |||
| Average Diluted Shares Outstanding | 6.98% | 4.49% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||